New Two-Drug attack on Hard-to-Treat myeloma enters early human tests
NCT ID NCT07280013
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers will also check whether the drugs shrink tumors. Participants will take cemsidomide for two weeks on and two weeks off, plus elranatamab injections twice a month.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemsidomide (oral drug) and elranatamab (injectable antibody)
What this could lead to
If this works, it could offer a new treatment option for people with multiple myeloma that has come back after other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 60 people. The main goal is safety, not proof of effectiveness. Side effects or lack of response are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Banner MD Anderson Cancer Center
NOT_YET_RECRUITINGGilbert, Arizona, 85234, United States
-
Dartmouth-Hitchcock Medical Center
NOT_YET_RECRUITINGLebanon, New Hampshire, 03756, United States
-
Duke Cancer Center
NOT_YET_RECRUITINGDurham, North Carolina, 27710, United States
-
Huntsman Cancer Institute, University of Utah
NOT_YET_RECRUITINGSalt Lake City, Utah, 84112, United States
-
Indiana University
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
-
Loyola University Medical Center
NOT_YET_RECRUITINGMaywood, Illinois, 60153, United States
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10021, United States
-
Norton Cancer Institute St. Matthews
NOT_YET_RECRUITINGLouisville, Kentucky, 40207, United States
-
Perlmutter Cancer Center at NYU Langone Hospital
NOT_YET_RECRUITINGBrooklyn, New York, 11203, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Tampa General Hospital
NOT_YET_RECRUITINGTampa, Florida, 33606, United States
-
UCLA Health, Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITINGSanta Monica, California, 90404, United States
-
University of Maryland Greenbaum Comprehensive Cancer Center
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
-
University of Nebraska
NOT_YET_RECRUITINGOmaha, Nebraska, 68105, United States
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States